Tesamorelin Canada: What the Record and Trials Actually Say

Searching tesamorelin canada can produce a confusing mix of old drug records, current catalogue listings, and broad claims about abdominal fat. The central distinction is straightforward but important: Health Canada issued Egrifta, a tesamorelin prescription drug, a Notice of Compliance in 2014. The current Drug Product Database, however, lists its 2 mg DIN as Cancelled Pre-Market and its 1 mg DIN as Cancelled Post-Market, effective September 30, 2022.

That history does not tell us that a Canadian prescription product is currently marketed. It also does not turn tesamorelin’s clinical-trial results into evidence for ordinary midlife weight management. The human evidence is real, but it comes mainly from adults living with HIV and HIV-associated abdominal fat accumulation.

Research Confidence

★★★★☆ The evidence is based on several randomized, placebo-controlled human trials, including two phase 3 trials pooled across 806 participants. They used CT scans to measure internal abdominal fat over 26 weeks. Confidence drops sharply when the question shifts to menopause, healthy aging, or general weight management, which these trials did not test.

Study Snapshot

• Study type: pooled analysis of two multicentre, randomized, double-blind, placebo-controlled phase 3 trials
• Participants: 806 adults receiving antiretroviral therapy for HIV with excess abdominal fat, about 15% women
• Duration: 26 weeks, with an additional 26-week blinded extension for eligible participants
• Measured: percentage change in CT-measured visceral adipose tissue, meaning fat stored around internal abdominal organs
• Found: placebo-adjusted visceral-fat change was -15.4% at week 26; body-mass index did not differ significantly between groups
• Funding: Theratechnologies affiliations and company-associated authors were reported

Why This Matters: Tesamorelin Canada Is Not a Simple Availability Search

For someone noticing more abdominal weight in midlife, a scan-based reduction in deep abdominal fat can sound like an answer to a familiar frustration. But visceral fat and body weight are not interchangeable. A CT scan can show a change in fat around organs even when the scale and body-mass index, or BMI, barely move.

That distinction matters because the leading tesamorelin trials were built around a specific HIV-related body-composition problem, not the gradual changes around perimenopause, menopause, aging, or a busy decade of life. The trials provide a useful example of why weight-management research needs careful reading: what was measured determines what a result can mean.

The Canadian Record: An Authorization Is Not Proof of Current Marketing

Health Canada issued Egrifta a Notice of Compliance on April 29, 2014. A Notice of Compliance is Health Canada’s authorization for a prescription drug to be marketed after its review. That is a historical regulatory fact, not a standing statement about present availability.

Current Drug Product Database entries list Egrifta 2 mg per vial, DIN 02423677, as Cancelled Pre-Market, and Egrifta 1 mg per vial, DIN 02438712, as Cancelled Post-Market. The latter cancellation took effect September 30, 2022. A DIN is a Drug Identification Number assigned to an authorized drug product; a cancelled DIN should not be read as confirmation that the product remains marketed in Canada.

The regulatory records reviewed here also do not establish whether tesamorelin could be compounded in Canada or whether any particular research-use supply has a Canadian legal pathway. Those are separate questions, and they cannot be answered from an old authorization alone.

The Core Trials: Internal Abdominal Fat, Not General Weight Loss

The largest evidence base comes from randomized, double-blind, placebo-controlled trials in people with HIV receiving antiretroviral therapy and living with excess abdominal fat. Randomized means participants were assigned by chance; double-blind means neither participants nor investigators knew who received tesamorelin or placebo during the blinded phase.

In the pooled phase 3 analysis, 806 participants received tesamorelin 2 mg by subcutaneous injection once daily or an identical placebo for 26 weeks. CT imaging estimated visceral adipose tissue. At week 26, the placebo-adjusted change was -15.4%. BMI did not differ significantly between groups. In plain terms, the programme recorded less deep abdominal fat on scans without demonstrating a meaningful difference in BMI.

An earlier 26-week randomized trial of 412 participants reported a 15.2% reduction in visceral fat with tesamorelin, compared with a 5.0% increase with placebo. Overall discontinuation was 20.5%, with no statistically significant difference in discontinuation between groups. That is a substantial number of people who did not complete the trial, even though it was not higher in one group than the other.

A Narrower Question: Liver-Fat Measurements in HIV Studies

The same clinical setting also prompted researchers to examine liver fat. In a 50-person randomized, double-blind, placebo-controlled trial lasting six months, the difference in visceral-fat change between groups was -42 cm². MRI-based liver-fat measurement also fell more in the tesamorelin group. Fasting glucose rose temporarily at two weeks in the tesamorelin group, while the difference between groups at six months was not statistically significant.

A separate 12-month randomized, double-blind, placebo-controlled trial enrolled 61 people with HIV and MRI-defined fatty liver. The estimated between-group difference in liver-fat change was -4.1 percentage points. Glucose measures did not differ between groups at 12 months, while local injection-site complaints were more common with tesamorelin.

These were meaningful, carefully measured outcomes in selected participants. They do not answer whether tesamorelin changes the course of fatty liver, reduces clinical events, or produces the same scan findings in people without HIV.

What This Means For You: A Scan Result Is Not a Midlife Weight-Loss Promise

If your real question is whether something could shift the abdominal changes of midlife, the honest answer is that these trials do not establish it. They were not designed for menopause-related body-composition changes, and they did not make scale weight their central outcome.

A useful conversation with a clinician can separate concerns that are often bundled together: waist size, overall weight, blood sugar, liver-fat risk, medication effects, sleep, and changes in muscle mass. They are related, but they are not one problem with one measurement.

It is also worth understanding how a trial measured its result before attaching personal meaning to it. Our guide to understanding research peptides explains why trial population, comparator, and endpoint matter as much as the headline finding.

What This Tells Us About Women Specifically: Tesamorelin Canada Evidence Has a Major Menopause Gap

Women accounted for about 15% of participants in the pooled 806-person phase 3 analysis. The investigators reported that the direction and size of visceral-fat change appeared similar in female and male subgroups, but the female subgroup was small.

Menopausal status was not reported. Neither was hormone-therapy use, and the major trials did not report outcomes designed around perimenopausal or postmenopausal body-composition change. That missing context matters: hormonal transition can affect where fat is stored, muscle mass, sleep, and metabolic markers. The available data cannot tell a midlife woman whether the HIV-study result applies to her situation.

Questions This Study Couldn't Answer: Current Access, Long-Term Outcomes, and Broader Populations

• Whether there is a currently marketed Canadian prescription tesamorelin product after the Egrifta DIN cancellations.
• Whether findings in HIV-associated abdominal fat accumulation apply to people without HIV.
• Whether CT or MRI changes lead to fewer clinical events, better daily function, or durable outcomes beyond the trial periods.
• How results differ by menopausal status, hormone therapy, or other sex-specific factors.
• Whether the company involvement in the phase 3 programme influenced any aspect of interpretation; disclosure provides context but cannot answer that question by itself.

Future Research: The Studies Needed Beyond HIV-Associated Abdominal Fat

Confidence for the broader tesamorelin canada search would rise with independently funded randomized trials in non-HIV populations. Those studies would need longer follow-up, clear reporting of discontinuations and adverse events, and results separated by sex and menopausal status. Patient-important outcomes, rather than imaging alone, would make the evidence more useful in real life.

Research Use And Availability

Nuforme lists tesamorelin as a research material in Canada. It is designated for research use only and is not presented here as a currently marketed Canadian prescription drug or as a substitute for clinical care. The evidence discussed above is human clinical research in a defined HIV population; it should not be treated as evidence of an outcome in other settings.

Final Thoughts: The Honest Answer Behind Tesamorelin Canada

Tesamorelin has been tested in people, and the strongest trials recorded reductions in CT-measured visceral abdominal fat among adults with HIV-associated abdominal fat accumulation. That is more substantive than a laboratory-only evidence base. But a historic Canadian drug authorization does not establish current marketing, and the trials do not answer the broader midlife weight-management question that often sits behind a search for tesamorelin canada.